Advertisement

Baseline Immune Activation as a Risk Factor for the Onset of Depression During Interferon-Alpha Treatment

Published:February 17, 2006DOI:https://doi.org/10.1016/j.biopsych.2005.11.024

      Background

      Major depression has been associated cross-sectionally with increased cell-mediated immune activation but causality has been difficult to establish. This study prospectively investigated the hypothesis that baseline level of immune activation predicts the development of depression during interferon-alpha (IFN-α) treatment.

      Methods

      Sixteen hepatitis C patients without psychiatric disorder underwent IFN-α treatment. Proinflammatory and anti-inflammatory cytokines were determined before starting treatment. Presence of a major depressive disorder (MDD) was assessed at baseline and several times during treatment.

      Results

      Baseline soluble interleukin-2 receptor (sIL-2r), interleukin-6 (IL-6), and interleukin-10 (IL-10) concentrations were significantly increased in the five subjects that developed MDD during treatment compared with those that did not, with standardized effect sizes of 1.08, 1.16, and 1.25, respectively, controlling for marijuana use, cigarette smoking, and baseline level of depressive symptoms.

      Conclusions

      Results suggest that increased immune activation, rather than an epiphenomenon, is a causal risk factor for the development of MDD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bonaccorso S.
        • Marino V.
        • Biondi M.
        • Grimaldi F.
        • Ippoliti F.
        • Maes M.
        Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus.
        J Affect Disord. 2002; 72: 237-241
        • Capuron L.
        • Ravaud A.
        • Miller A.H.
        • Dantzer R.
        Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
        Brain Behav Immun. 2004; 18: 205-213
        • Dieperink E.
        • Ho S.B.
        • Thuras P.
        • Willenbring M.L.
        A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.
        Psychosomatics. 2003; 44: 104-112
        • Gottesman I.I.
        • Gould T.D.
        The endophenotype concept in psychiatry.
        Am J Psychiatry. 2003; 160: 636-645
        • Hauser P.
        • Khosla J.
        • Aurora H.
        • Laurin J.
        • Kling M.A.
        • Hill J.
        • et al.
        A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
        Mol Psychiatry. 2002; 7: 942-947
        • Horikawa N.
        • Yamazaki T.
        • Izumi N.
        • Uchihara M.
        Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy.
        Gen Hosp Psychiatry. 2003; 25: 34-38
        • Loftis J.M.
        • Socherman R.E.
        • Howell C.D.
        • Whitehead A.J.
        • Hill J.A.
        • Dominitz J.A.
        • et al.
        Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.
        Neurosci Lett. 2004; 365: 87-91
        • Maes M.
        Evidence for an immune response in major depression.
        Prog Neuropsychopharmacol Biol Psychiatry. 1995; 19: 11-38
        • Maes M.
        • Bosmans E.
        • De Jongh R.
        • Kenis G.
        • Vandoolaeghe E.
        • Neels H.
        Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.
        Cytokine. 1997; 9: 853-858
        • Meyaard L.
        • Hovenkamp E.
        • Otto S.A.
        • Miedema F.
        IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses.
        J Immunol. 1996; 156: 2776-2782
        • Mikova O.
        • Yakimova R.
        • Bosmans E.
        • Kenis G.
        • Maes M.
        Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis.
        Eur Neuropsychopharmacol. 2001; 11: 203-208
        • Montgomery S.A.
        • Asberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Naka T.
        • Nishimoto N.
        • Kishimoto T.
        The paradigm of IL-6.
        Arthritis Res. 2002; 4: S233-S242
        • Oppenheim J.J.
        • Ruscetti F.W.
        • Faltynek C.
        Cytokines.
        in: Stites D.P. Terr A.I. Parslow T. Basis & Clinical Immunology. Appleton & Lange, Stamford, CT1994: 870
        • Raison C.L.
        • Broadwell S.D.
        • Borisov A.S.
        • Manatunga A.K.
        • Capuron L.
        • Woolwine W.J.
        • et al.
        Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
        Brain Behav Immun. 2005; 19: 23-27
        • Sheehan D.V.
        • Lecrubier Y.
        • Sheehan K.H.
        • Amorim P.
        • Janavs J.
        • Weiller E.
        • et al.
        The Mini-International Neuropsychiatric Interview (M.I.N.I.).
        J Clin Psychiatry. 1998; 59: 22-57
        • Sluzewska A.
        • Rybakowski J.
        • Bosmans E.
        • Sobieska M.
        • Berghmans R.
        • Maes M.
        • et al.
        Indicators of immune activation in major depression.
        Psychiatry Res. 1996; 64: 161-167
        • Thomas A.J.
        • Davis S.
        • Morris C.
        • Jackson E.
        • Harrison R.
        • O’Brien J.T.
        Increase in interleukin-1{beta} in late-life depression.
        Am J Psychiatry. 2005; 162: 175-177
        • Tuglu C.
        • Kara S.H.
        • Caliyurt O.
        • Vardar E.
        • Abay E.
        Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.
        Psychopharmacology (Berl). 2003; 170: 429-433
        • Wichers M.
        • Koek G.
        • Robaeys G.
        • Praamstra A.
        • Maes M.
        Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes.
        Psychol Med. 2005; 34: 433-441
        • Wichers M.C.
        • Koek G.H.
        • Robaeys G.
        • Verkerk R.
        • Scharpe S.
        • Maes M.
        IDO and interferon-alpha-induced depressive symptoms.
        Mol Psychiatry. 2005; 10: 538-544
        • Zorrilla E.P.
        • Luborsky L.
        • McKay J.R.
        • Rosenthal R.
        • Houldin A.
        • Tax A.
        • et al.
        The relationship of depression and stressors to immunological assays.
        Brain Behav Immun. 2001; 15: 199-226